| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | SELL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.91▲ | 1.90▲ | 1.90▲ | 2.08▼ | 2.22▼ |
| MA10 | 1.91▲ | 1.89▲ | 1.92▼ | 2.14▼ | 2.56▼ |
| MA20 | 1.90▲ | 1.93▼ | 1.96▼ | 2.22▼ | 1.79▲ |
| MA50 | 1.89▲ | 2.04▼ | 2.11▼ | 2.57▼ | 1.35▲ |
| MA100 | 1.93▼ | 2.12▼ | 2.18▼ | 1.74▲ | 1.37▲ |
| MA200 | 2.02▼ | 2.20▼ | 2.37▼ | 1.36▲ | 2.85▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.007▲ | 0.001▲ | -0.029▼ | -0.023▼ |
| RSI | 58.479▲ | 40.300▼ | 37.514▼ | 34.980▼ | 52.267▲ |
| STOCH | 41.667 | 62.243 | 21.905 | 26.146 | 40.234 |
| WILL %R | -66.667 | -65.517 | -65.517 | -89.744▼ | -50.004 |
| CCI | 172.464▲ | 32.906 | -37.086 | -192.427▼ | -28.907 |
|
Wednesday, August 13, 2025 05:34 AM
Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.38. Operator: Good afternoon, and welcome to Spero ...
|
|
Wednesday, August 13, 2025 02:23 AM
PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...
|
|
Wednesday, August 13, 2025 12:37 AM
Spero Therapeutics Inc (SPRO) reports strong revenue growth and cost savings, despite challenges in the SPR 720 program.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 1.95 | 1.96 | 1.85 | 1.91 | 1,046,944 |
| 14/08/25 | 1.92 | 2.005 | 1.918 | 1.98 | 626,243 |
| 13/08/25 | 2.15 | 2.15 | 1.92 | 1.935 | 2,491,150 |
| 12/08/25 | 2.21 | 2.38 | 2.21 | 2.36 | 677,646 |
| 11/08/25 | 2.19 | 2.23 | 2.15 | 2.20 | 360,244 |
| 08/08/25 | 2.16 | 2.225 | 2.16 | 2.19 | 402,219 |
| 07/08/25 | 2.25 | 2.27 | 2.125 | 2.17 | 1,003,359 |
| 06/08/25 | 2.15 | 2.31 | 2.15 | 2.26 | 817,747 |
| 05/08/25 | 2.29 | 2.33 | 2.11 | 2.12 | 2,317,529 |
| 04/08/25 | 2.32 | 2.39 | 2.20 | 2.26 | 950,419 |
|
|
||||
|
|
||||
|
|